LSV Asset Management Sells 8,300 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

LSV Asset Management lessened its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 0.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,057,300 shares of the company’s stock after selling 8,300 shares during the period. LSV Asset Management’s holdings in Amneal Pharmaceuticals were worth $6,714,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of AMRX. Rubric Capital Management LP raised its position in shares of Amneal Pharmaceuticals by 98.8% during the fourth quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company’s stock worth $48,560,000 after acquiring an additional 3,975,500 shares during the last quarter. Hennessy Advisors Inc. acquired a new stake in Amneal Pharmaceuticals in the second quarter worth about $8,818,000. Acadian Asset Management LLC raised its holdings in Amneal Pharmaceuticals by 701.8% during the 2nd quarter. Acadian Asset Management LLC now owns 811,853 shares of the company’s stock worth $5,148,000 after purchasing an additional 710,598 shares during the last quarter. Hillsdale Investment Management Inc. boosted its stake in shares of Amneal Pharmaceuticals by 1,240.3% in the 4th quarter. Hillsdale Investment Management Inc. now owns 584,619 shares of the company’s stock valued at $3,549,000 after purchasing an additional 541,000 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Amneal Pharmaceuticals by 271.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 546,537 shares of the company’s stock valued at $3,312,000 after purchasing an additional 399,492 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Truist Financial increased their price objective on shares of Amneal Pharmaceuticals from $9.00 to $10.00 and gave the company a “buy” rating in a report on Monday, August 12th. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target on the stock in a research note on Friday, September 6th. Finally, Barclays lifted their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $9.00.

Amneal Pharmaceuticals Trading Down 0.2 %

NASDAQ AMRX opened at $8.36 on Thursday. The company has a debt-to-equity ratio of 121.31, a current ratio of 1.33 and a quick ratio of 0.82. The stock’s 50-day moving average is $7.70 and its 200-day moving average is $6.72. Amneal Pharmaceuticals, Inc. has a one year low of $3.36 and a one year high of $8.72. The firm has a market cap of $2.59 billion, a P/E ratio of -14.93 and a beta of 1.18.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Friday, August 9th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.04. The firm had revenue of $701.78 million for the quarter, compared to analyst estimates of $657.43 million. Amneal Pharmaceuticals had a negative net margin of 6.72% and a positive return on equity of 1,235.03%. Sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.52 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.